The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study
Introduction: in Brazil, chronic hepatitis C in patients coinfected with the human immunodeficiency virus (HIV) is treated with pegylated interferon (Peg-IFN) and ribavirin (RBV). However, few studies have evaluated the effectiveness of this treatment in this particular population. The identification of the factors that predict sustained virological response (SVR) under current clinical practice would enable clinicians to more accurately estimate the probability of achieving an SVR and therefore utilize the appropriate therapeutics, especially in the era of direct-acting antiviral (DAA) agents.Aims: the primary aim of our study was to determine the SVR rate under current clinical practice. The secondary aims were as follows: (1) to determine the factors before and during treatment that predict SVR; and (2) to identify the causes of treatment interruption.Methods:within a cohort of HIV/hepatitis C virus (HCV)-coinfected patients in Brazil, we performed a retrospective analysis of those individuals treated with Peg-IFN and RBV.Results:among the 382 analyzed patients, SVR was observed in 118 [30.9% (95% confidence interval (CI): 26.3-35.8)], which included 25.9% (75/289) of the patients with genotypes 1 and 4 and 48.2% (41/85) of those with genotypes 2 and 3. After multivariate analyses the independent positive predictors for SVR after treatment for chronic hepatitis C with PegIFN and RBV were: absence of an AIDS-defining illness (p= 0.001), HCV viral load lower than 600,000 IU/mL at the onset of treatment (p= 0.003), higher liver enzyme levels (p= 0.039) at baseline, infection with genotypes 2 or 3 (p= 0.003), and no transient treatment interruption (p= 0.001). The treatment was interrupted in 25.6% (98/382) of the patients because of adverse events (11.3%, 43/382), virologic failure (7.8%, 30/382), and dropout (6.5%, 43/382). The main adverse events were cytopenia and psychiatric disorders.Conclusions:in our Brazilian case series, the SVR rate under current clinical practice conditions was similar to that reported in other studies. There was a correlation between an SVR and being infected by genotypes 2 and 3, low viral load, high ALT levels at the onset of treatment, and absence of an AIDS-defining illness. Cytopenia and psychiatric disorders were the major causes of treatment interruption. Efforts should be focused on optimizing management of side effects and counseling to improve adherence and to keep patients on treatment.
Main Authors: | , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Brazilian Society of Infectious Diseases
2015
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000100015 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S1413-86702015000100015 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S1413-867020150001000152015-10-26The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric studyFerreira,Paulo Roberto AbrãoSilva,Mariliza Henrique daBrandão-Melo,Carlos EduardoRezende,Rosamar EuliraGonzalez,MárioReuter,TâniaUrbaez,Jose DavidGianini,Reinaldo JoseMartinelli,AnaMendes-Correa,Maria Cássia Interferon Ribavirin HCV HIV Introduction: in Brazil, chronic hepatitis C in patients coinfected with the human immunodeficiency virus (HIV) is treated with pegylated interferon (Peg-IFN) and ribavirin (RBV). However, few studies have evaluated the effectiveness of this treatment in this particular population. The identification of the factors that predict sustained virological response (SVR) under current clinical practice would enable clinicians to more accurately estimate the probability of achieving an SVR and therefore utilize the appropriate therapeutics, especially in the era of direct-acting antiviral (DAA) agents.Aims: the primary aim of our study was to determine the SVR rate under current clinical practice. The secondary aims were as follows: (1) to determine the factors before and during treatment that predict SVR; and (2) to identify the causes of treatment interruption.Methods:within a cohort of HIV/hepatitis C virus (HCV)-coinfected patients in Brazil, we performed a retrospective analysis of those individuals treated with Peg-IFN and RBV.Results:among the 382 analyzed patients, SVR was observed in 118 [30.9% (95% confidence interval (CI): 26.3-35.8)], which included 25.9% (75/289) of the patients with genotypes 1 and 4 and 48.2% (41/85) of those with genotypes 2 and 3. After multivariate analyses the independent positive predictors for SVR after treatment for chronic hepatitis C with PegIFN and RBV were: absence of an AIDS-defining illness (p= 0.001), HCV viral load lower than 600,000 IU/mL at the onset of treatment (p= 0.003), higher liver enzyme levels (p= 0.039) at baseline, infection with genotypes 2 or 3 (p= 0.003), and no transient treatment interruption (p= 0.001). The treatment was interrupted in 25.6% (98/382) of the patients because of adverse events (11.3%, 43/382), virologic failure (7.8%, 30/382), and dropout (6.5%, 43/382). The main adverse events were cytopenia and psychiatric disorders.Conclusions:in our Brazilian case series, the SVR rate under current clinical practice conditions was similar to that reported in other studies. There was a correlation between an SVR and being infected by genotypes 2 and 3, low viral load, high ALT levels at the onset of treatment, and absence of an AIDS-defining illness. Cytopenia and psychiatric disorders were the major causes of treatment interruption. Efforts should be focused on optimizing management of side effects and counseling to improve adherence and to keep patients on treatment.info:eu-repo/semantics/openAccessBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious Diseases v.19 n.1 20152015-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000100015en10.1016/j.bjid.2014.08.002 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Ferreira,Paulo Roberto Abrão Silva,Mariliza Henrique da Brandão-Melo,Carlos Eduardo Rezende,Rosamar Eulira Gonzalez,Mário Reuter,Tânia Urbaez,Jose David Gianini,Reinaldo Jose Martinelli,Ana Mendes-Correa,Maria Cássia |
spellingShingle |
Ferreira,Paulo Roberto Abrão Silva,Mariliza Henrique da Brandão-Melo,Carlos Eduardo Rezende,Rosamar Eulira Gonzalez,Mário Reuter,Tânia Urbaez,Jose David Gianini,Reinaldo Jose Martinelli,Ana Mendes-Correa,Maria Cássia The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study |
author_facet |
Ferreira,Paulo Roberto Abrão Silva,Mariliza Henrique da Brandão-Melo,Carlos Eduardo Rezende,Rosamar Eulira Gonzalez,Mário Reuter,Tânia Urbaez,Jose David Gianini,Reinaldo Jose Martinelli,Ana Mendes-Correa,Maria Cássia |
author_sort |
Ferreira,Paulo Roberto Abrão |
title |
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study |
title_short |
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study |
title_full |
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study |
title_fullStr |
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study |
title_full_unstemmed |
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study |
title_sort |
clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis c in hiv-infected patients in brazil: a multicentric study |
description |
Introduction: in Brazil, chronic hepatitis C in patients coinfected with the human immunodeficiency virus (HIV) is treated with pegylated interferon (Peg-IFN) and ribavirin (RBV). However, few studies have evaluated the effectiveness of this treatment in this particular population. The identification of the factors that predict sustained virological response (SVR) under current clinical practice would enable clinicians to more accurately estimate the probability of achieving an SVR and therefore utilize the appropriate therapeutics, especially in the era of direct-acting antiviral (DAA) agents.Aims: the primary aim of our study was to determine the SVR rate under current clinical practice. The secondary aims were as follows: (1) to determine the factors before and during treatment that predict SVR; and (2) to identify the causes of treatment interruption.Methods:within a cohort of HIV/hepatitis C virus (HCV)-coinfected patients in Brazil, we performed a retrospective analysis of those individuals treated with Peg-IFN and RBV.Results:among the 382 analyzed patients, SVR was observed in 118 [30.9% (95% confidence interval (CI): 26.3-35.8)], which included 25.9% (75/289) of the patients with genotypes 1 and 4 and 48.2% (41/85) of those with genotypes 2 and 3. After multivariate analyses the independent positive predictors for SVR after treatment for chronic hepatitis C with PegIFN and RBV were: absence of an AIDS-defining illness (p= 0.001), HCV viral load lower than 600,000 IU/mL at the onset of treatment (p= 0.003), higher liver enzyme levels (p= 0.039) at baseline, infection with genotypes 2 or 3 (p= 0.003), and no transient treatment interruption (p= 0.001). The treatment was interrupted in 25.6% (98/382) of the patients because of adverse events (11.3%, 43/382), virologic failure (7.8%, 30/382), and dropout (6.5%, 43/382). The main adverse events were cytopenia and psychiatric disorders.Conclusions:in our Brazilian case series, the SVR rate under current clinical practice conditions was similar to that reported in other studies. There was a correlation between an SVR and being infected by genotypes 2 and 3, low viral load, high ALT levels at the onset of treatment, and absence of an AIDS-defining illness. Cytopenia and psychiatric disorders were the major causes of treatment interruption. Efforts should be focused on optimizing management of side effects and counseling to improve adherence and to keep patients on treatment. |
publisher |
Brazilian Society of Infectious Diseases |
publishDate |
2015 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702015000100015 |
work_keys_str_mv |
AT ferreirapaulorobertoabrao theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT silvamarilizahenriqueda theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT brandaomelocarloseduardo theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT rezenderosamareulira theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT gonzalezmario theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT reutertania theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT urbaezjosedavid theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT gianinireinaldojose theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT martinelliana theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT mendescorreamariacassia theclinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT ferreirapaulorobertoabrao clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT silvamarilizahenriqueda clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT brandaomelocarloseduardo clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT rezenderosamareulira clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT gonzalezmario clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT reutertania clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT urbaezjosedavid clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT gianinireinaldojose clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT martinelliana clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy AT mendescorreamariacassia clinicaleffectivenessofpegylatedinterferonandribavirinforthetreatmentofchronichepatitiscinhivinfectedpatientsinbrazilamulticentricstudy |
_version_ |
1756416497683529728 |